GE HealthCare Technologies (GEHC) has quietly pushed higher recently, with the stock up about 15% over the past month and roughly 8% in the past 3 months, outpacing many healthcare peers.
See our latest analysis for GE HealthCare Technologies.
Zooming out, the stock’s roughly 15% 1 month share price return and 7.8% year to date share price return, alongside a modest 1 year total shareholder return of just over 2%, point to momentum that has picked up recently rather than been sustained all year.
If this kind of steady healthcare move has your attention, it could be a good time to see what else is setting up well across healthcare stocks.
With shares now trading just below analyst targets but still at a sizable discount to some intrinsic value estimates, is GE HealthCare quietly undervalued or already reflecting the bulk of its future growth potential?
Most Popular Narrative: 5.3% Undervalued
GE HealthCare Technologies last closed at $84.47, a touch below the most followed fair value estimate of $89.21, framing a modest upside story.
The pipeline of new high impact products, like Radiopharmaceuticals, Total Body PET, and Photon Counting CT, is anticipated to drive future revenue growth and potentially improve margins.
Want to see why steady growth assumptions still point to upside? This narrative focuses on margin resilience, disciplined discounting, and a valuation multiple that is more conservative than many sector leaders. Curious which forecasts really move the dial on that fair value line? Explore the earnings and revenue path that supports this price.
Result: Fair Value of $89.21 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still meaningful risks around China policy and tariff uncertainty that could pressure margins, dampen earnings growth, and challenge that upside case.
Find out about the key risks to this GE HealthCare Technologies narrative.
Build Your Own GE HealthCare Technologies Narrative
If you see the story differently or want to test your own assumptions, you can build a personalized view in just minutes: Do it your way.
A great starting point for your GE HealthCare Technologies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
Looking for your next smart move?
Before momentum shifts again, consider your next watchlist upgrades using our targeted screeners, built to uncover opportunities many investors overlook until it is too late.
- Explore early-stage growth potential by focusing on these 3602 penny stocks with strong financials that combine smaller market caps with solid fundamentals.
- Align your portfolio with the evolving tech landscape by reviewing these 26 AI penny stocks connected to demand for intelligent automation.
- Reinforce your portfolio’s income component with these 12 dividend stocks with yields > 3% that feature yields supported by cash flows.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if GE HealthCare Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com